Targeted Therapy Shows Benefit in Rare Type of Thyroid Cancer

Treatment with the multitargeted agent vandetanib (Caprelsa) improved progression-free survival in patients with medullary thyroid cancer (MTC), according to findings from a randomized clinical trial. Earlier this year, the Food and Drug Administration (FDA) approved vandetanib for the treatment of patients with MTC based on initial findings from the phase III trial. MTC is a rare cancer, accounting for only 5 percent of all thyroid cancer cases, and radiation and chemotherapy have limited effects once the cancer progresses to an advanced stage.
NCI Cancer Bulletin

Music 4 Cancer- Cause

Preventing a Stroke

Prepackaged (7 3/4 in.) Cancer Awareness Bracelet 18 Colors, 8mm
Product Description
Our Bracelets are Handmade in the USA. Made with 8mm cats eye beads (the red bead here is a glass pearl, not a…

Breast Cancer Pink Ribbon Lanyard – RETAIL
This pink ribbon lanyard has dark pink ribbons along with the words “Find The Cure” in white letters. Can act as a keychain or bad…